drugset / Trial / NCT06835322

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

NCT06835322

Phase 2 Completed 100 enrolled Alexandria University
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.

Timeline

Start
2025-04-01
Primary completion
2026-03-01
Completion
2026-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Finerenone Small molecule 10 mg Oral
Subject Finerenone Small molecule 20 mg Oral

Indications